Express News | Taysha Gene Therapies Announces Oral Presentation on Tsha-102 in Rett Syndrome at Upcoming 9TH World Rett Syndrome Congress
Truist Financial Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Taysha Gene Therapies(TSHA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.4% and a total average return of 20.8%
Express News | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Taysha Gene Therapies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5
BMO Capital analyst Keith Tapper CFA maintains $Taysha Gene Therapies(TSHA.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 80
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $5 to $7
On Aug 14, major Wall Street analysts update their ratings for $Taysha Gene Therapies(TSHA.US)$, with price targets ranging from $5 to $7.BMO Capital analyst Keith Tapper CFA maintains with a buy